| PAT. NO. |
Title |
|
7,160,681
|
Method for regulating cell growth and assays related thereto |
|
7,090,865
|
Composition and method for treating autoimmune hemolytic anemia |
|
6,974,677
|
Human MEKK proteins, corresponding nucleic acid molecules, and uses therefor |
|
6,951,733
|
Method for testing drug susceptibility of Mycobacterium tuberculosis |
|
6,916,799
|
Substituted Porphyrins |
|
6,875,749
|
Methods for facilitating vascular growth |
|
6,737,398
|
Modulation of gamma delta T cells to regulate airway hyperresponsiveness |
|
6,693,086
|
Systemic immune activation method using nucleic acid-lipid complexes |
|
6,579,694
|
Agar medium for the growth of Mycobacterium tuberculosis |
|
6,576,433
|
Method for identification of cell growth or differentiation factors |
|
6,555,318
|
Method for identification of cell growth or differentiation factors |
|
6,544,975
|
Substituted porphyrins |
|
6,503,509
|
Method for receptor desensitization |
|
6,500,430
|
Product and process to regulate actin polymerization in T lymphocytes |
|
6,497,840
|
Ultraviolet germicidal system |
|
6,495,331
|
Regulation of cytokine production in a hematopoietic cell |
|
6,479,477
|
Substituted porphyrins |
|
6,475,987
|
Tall-1 receptor homologues |
|
6,399,607
|
Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin |
|
6,333,170
|
Method and product for regulating cell responsiveness to external signals |
|
6,312,934
|
Human MEKK proteins, corresponding nucleic acid molecules, and uses therefor |
|
6,306,612
|
Methods of facilitating vascular growth |
|
6,264,950
|
Product and process for T lymphocyte immunosuppression |
|
6,264,888
|
Ultraviolet germicidal apparatus and method |
|
6,248,723
|
Method for treatment of inflammatory disease |
|
6,231,894
|
Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase |
|
6,187,584
|
Products and processes for regulation of gene recombination |
|
6,156,503
|
Diagnosing asthma patients predisposed to adverse .beta.-agonist reactions |
|
6,132,978
|
Method to regulate CD40 signaling |
|
6,110,739
|
Method to produce novel embryonic cell populations |
|
6,074,861
|
MEKK proteins |
|
6,060,054
|
Product for T lymphocyte immunosuppression |
|
6,040,152
|
Method and assay for regulation of T cell proliferation |
|
5,985,261
|
Use of thioredoxin-like molecules for induction of MnSOD to treat oxidative damage |
|
5,981,265
|
Methods for regulating MEKK protein activity |
|
5,976,819
|
Product and process to regulate actin polymerization in T lymphocytes |
|
5,976,786
|
Screening methods for the identification of compounds that modulate apoptosis in immunodeficiency virus infected cells |
|
5,959,074
|
Products and processes for regulation of gene recombination |
|
5,935,568
|
Gene therapy for effector cell regulation |
|
5,914,268
|
Embryonic cell populations and methods to isolate such populations |
|
5,910,417
|
Regulation of cytokine production in a hematopoietic cell |
|
5,908,620
|
Treatment for diseases involving inflammation |
|
5,906,815
|
Treatment for diseases involving inflammation |
|
5,874,301
|
Embryonic cell populations and methods to isolate such populations |
|
5,854,043
|
MEKK-related signal transduction kinases |
|
5,851,786
|
Product and process to regulate actin polymerization |
|
5,820,866
|
Product and process for T cell regulation |
|
5,753,446
|
Mitogen ERK kinase kinase (MEKK) assay |
|
5,705,151
|
Gene therapy for T cell regulation |
|
5,698,679
|
Product and process for targeting an immune response |
|
5,674,483
|
Treatment for diseases involving inflammation |
|
5,567,590
|
Methods of diagnosing steroid-resistant inflammation due to type I or type II nuclear glucocorticoid receptor binding abnormalities |
|
5,470,835
|
Transfer factor and methods of use |
|
5,405,941
|
MEKK protein, capable of phosphorylating MEK |
